AzoMaxActive Clinical trial results

Clinical areas cleaned with AzoMaxActive will contain significantly fewer micro-organisms than clinical areas cleaned with chlorine releasing agents (or neutral detergents). Reducing the environmental bacterial load reduces the HCAI risk to patients by reducing the opportunity for patients to come into contact with potentially pathogenic micro-organisms.

Up to week five all study wards were similar in terms of TVCs. From week six onwards AzoMaxActive wards demonstrate a significant and sustained reduction in TVCs (Figure 1). This divergence in TVC trend lines reflects the build-up of a biocidal nano-layer which continues working even after the product has dried and is a key feature of AzoMaxActive.

The low numbers of environmental MRSA and C. difficile detected within the study environment preclude any firm conclusions being drawn from the data at this point. At six months the incidence of C. difficile or MRSA infection is equivalent on all wards.

Based on the six month data analysis AzoMaxActive is clinically proven to significantly outperform chlorine releasing agents in terms of TVCs and it appears to be at least as effective as chlorine releasing agents in terms of reducing environmental levels of MRSA and C. difficile.

The cleaner the clinical environment the lower the HCAI risk to the patient. In terms of cleaning the clinical environment; AzoMaxActive outperforms hypochlorite which outperforms neutral detergent. Therefore AzoMaxActive offers the greatest HCAI risk reduction in clinical areas that are currently cleaned with neutral detergent. Areas cleaned with neutral detergent are likely to report higher levels of environmental bioburden and therefore have the most to gain by switching to an AzoMaxActive cleaning regime.

AzoMaxActive (containing ByotrolTM technology) is non-toxic, non-hazardous, safe to use, requires no specialist equipment or training and offers healthcare staff the opportunity to practice ‘evidence based’ healthcare disinfection to reduce the HCAI risk to their patients.